A clinical trial looking at combination of two popular lung cancer drugs Tarceva and Avastin showed that the drugs given together for lung cancer treatment do not increase survival rates. Tarceva is marketed by Genentech and Avastin by Roche. Both drugs are already widely available in US and Europe as lung cancer treatment. Both drugs belong to a series of drugs under targeted therapies – innovative drugs that are also called ‘smart bombs’ because they are able to differ cancerous cells from healthy ones and kill those affected by the disease. Lung Cancer Symptoms and Treatment Genentech and Roche initiated Phase III clinical trial to see if the drug combination can provide with better survival rates to advanced non-small cell lung cancer, which is the most common and deadly type of lung cancer. Researchers reported that drug...
[read full story]
Your Web Site
